Generated by AI
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform. The company works on off-the-shelf CAR-T and CAR-NK therapies designed to support precise cell engineering for difficult-to-treat diseases. Its current pipeline centers on hematologic malignancies and autoimmune disorders, with programs that include anti-CD19, anti-BCMA, and anti-CD371 cell therapies in clinical development. Caribou Biosciences also applies its gene-editing technology to advance broader research and therapeutic applications in biotechnology. Headquartered in Berkeley, California, the company operates as a single business segment centered on next-generation cell therapy development.
Website2929 7th Street
Berkeley, CA, 94710
United States
The latest articles about CRBU.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 7's posts. Generated by AI.
Summary of Aug 17's posts. Generated by AI.
Summary of Oct 9's posts. Generated by AI.
Investors talking about CRBU also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.